← Markets

The Cooper Companies, Inc.

COO · NASDAQ

Market closed$71.71$-1.39 (-1.90%)After hours $71.71 · 0.00%

Key statistics

Previous close$73.10
Open$73.10
Day high$73.95
Day low$71.45
52-week high$89.83
52-week low$58.89
Market cap13.99B
Volume1.65M
Average volume2.93M
P/E ratio15.73
Forward P/E—
EPS4.56
Dividend yield0.00%

Market context

Why it moved

COO shares declined amid a broader technology and growth stock selloff, with semiconductor and high-flying market segments entering bear market territory, driving investors toward defensive sectors and weighing on medical device and growth-oriented stocks like Cooper Companies.

PolicymagazineStockinvestBusiness InsiderSeekingalphaNypost

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Cooper Companies declined nearly 2%, underperforming the broader healthcare sector (XLV), amid a risk-off session driven by escalating U.S.-Iran military exchanges and renewed AI growth concerns that weighed on equities broadly. Adding to the headwinds, Goldman Sachs reiterated a Sell rating with a reduced $63 price target, while a separate analyst cut their 12-month target to $81.25 — a divide that reflects the stock's mixed analyst sentiment. On the positive side, the Oakmark Global Fund disclosed a new position in COO, and Zacks highlighted the company's CooperVision premium lens growth and MiSight myopia management leadership as longer-term catalysts, though near-term challenges including Japan weakness, FX pressure, and a 13.8% year-to-date decline continue to weigh on sentiment.

-1.9015

July 16, 2026Cooper Companies rose sharply, buoyed by a combination of institutional interest and a broader healthcare sector rally. The Oakmark Global Fund's disclosure of a new position in COO sparked renewed buying enthusiasm, while strong momentum signals — including MACD and ADX buy indicators — drove the stock above its 20- and 50-day moving averages and just past the key 200-day resistance level. The healthcare sector gained tailwinds from UnitedHealth's better-than-expected Q2 earnings and raised guidance, lifting XLV. Analyst sentiment remains divided: Goldman Sachs reiterated a Sell with a $63 target, while Citigroup recently raised its target to $76, and the consensus average sits near $82.

3.5411

July 16, 2026The Cooper Companies closed sharply higher, rebounding from the prior session's 3.9% decline, as the broader healthcare sector and a softer-than-expected June CPI report lifted investor sentiment. The recovery came despite Goldman Sachs maintaining its Sell rating and trimming its price target to $63 from $66 — well below the current price — while the analyst consensus average target stands at $80.86. UBS also highlighted healthcare as a key sector allocation alongside the AI theme, citing improving earnings revisions and a stabilizing regulatory environment, which may have contributed to the renewed buying interest in medtech names like Cooper Companies.

3.0506

July 15, 2026Cooper Companies fell nearly 4%, pressured by a Goldman Sachs price target cut to $63 from $66 while maintaining a Sell rating — well below the Street's mean target of $80.38. The decline also came amid broader healthcare sector weakness, with peers like Abbott Labs and Stryker each falling over 3-5%, as investors brace for a reported 9% Q2 earnings drop across the sector ahead of key reports from J&J, UnitedHealth, and Abbott this week.

-3.94

July 14, 2026Cooper Companies edged higher, bucking a broadly defensive tone in equities as renewed U.S.-Iran tensions sent oil prices surging and weighed on growth stocks. The healthcare medtech name drew relative support from its steady demand profile in specialty contact lenses and women's health — sectors analysts view as resilient amid macro uncertainty. Analysts carry a consensus price target of ~$81.85 on COO, implying meaningful upside, even as the stock trades at a premium valuation and healthcare broadly posted mixed Q2 results ahead of a key earnings season.

0.8769

July 11, 2026Cooper Companies closed modestly lower, edging down as the broader healthcare sector (XLV) also retreated, though the stock is rebounding in after-hours trading. The key recent catalyst is Citigroup raising its price target to $76 from $69 while maintaining a Neutral rating — a modest but notable vote of confidence following a 3.2% slide on July 8. With an average analyst target of ~$81, investors are weighing the long-term appeal of CooperCompanies' recurring revenue from specialty contact lenses and fertility solutions against near-term valuation concerns, with Goldman Sachs maintaining a Sell rating and a $66 target.

-0.4506

July 9, 2026Cooper Companies fell sharply, pressured by a broad market risk-off selloff after President Trump declared the U.S.-Iran interim peace deal 'over,' sending oil prices surging over 5% and sparking global equity weakness. The decline came despite a constructive analyst development: Citigroup raised its price target on Cooper to $76 from $69, maintaining a Neutral rating — a signal of incremental confidence in the company's contact lens and fertility businesses even amid macro headwinds. With healthcare broadly outperforming other sectors in recent weeks (XLV up 6.6% in June), Cooper's drop outpaced the sector as investors rotated toward defensive names, while the stock remains well below the Street's average target of roughly $80.

-3.1715

July 8, 2026Cooper Companies edged lower, declining about 1%, as broader market weakness — with the S&P 500 and Nasdaq both pulling back on semiconductor drag and rising Treasury yields — weighed on the stock despite a constructive healthcare sector backdrop. The XLV health care ETF approached its 52-week high, reflecting ongoing sector rotation into healthcare from tech. Recent attention has centered on Cooper's 2025 Corporate Sustainability Report, which introduced first-time Scope 3 emissions disclosures, while analysts see shares trading roughly 8% below fair value with free cash flow expected to inflect higher as its multi-year MyDAY capacity build-out winds down.

-0.9916

TradingView · July 17, 2026The Cooper Companies, Inc. Stock 12‑Month Price Target Cut to $81.25, Implies 11% UpsideZacks Investment Research · July 17, 2026Reasons to Retain Cooper Companies Stock in Your Portfolio for NowAd Hoc News · July 17, 2026CooperCompanies stock trades steady as recent earnings highlight growth in contact lenses and womenVisionMonday.com · July 15, 2026CooperCompanies Releases 2025 Corporate Sustainability Report With Scope 3 Emissions Disclosuremarketscreener.com · July 14, 2026Goldman Sachs Adjusts Price Target on Cooper Companies to $63 From $66, Maintains Sell RatingMoomoo · July 14, 2026Goldman Sachs Adjusts Price Target on Cooper Companies to $63 From $66, Maintains Sell RatingSimply Wall Street · July 2, 2026Cooper’s Expanded ESG Disclosures and Scope 3 Emissions Data Might Change The Case For Investing In Cooper Companies (COO)
Mt Newswire · July 14, 2026Goldman Sachs Adjusts Price Target on Cooper Companies to $63 From $66, Maintains Sell Rating
Benzinga · July 8, 2026Citigroup Maintains Neutral on Cooper Companies, Raises Price Target to $76
Mt Newswire · July 8, 2026Citigroup Adjusts Cooper Price Target to $76 From $69
Benzinga · June 8, 2026BNP Paribas Maintains Outperform on Cooper Companies, Lowers Price Target to $92
Mt Newswire · June 8, 2026BNP Paribas Adjusts Price Target on Cooper to $92 From $95, Maintains Outperform Rating
Mt Newswire · June 5, 2026US Equity Indexes Plummet as Dwindling Expectations for Monetary Policy Easing Decimate Mega-Cap Technology
Benzinga · June 5, 2026JP Morgan Maintains Neutral on Cooper Companies, Lowers Price Target to $71
Benzinga · June 5, 2026Stifel Maintains Buy on Cooper Companies, Lowers Price Target to $85

Peers

S&P 500SPX · $7,457.78-1.01%Alcon Inc.ALC · $70.26-0.51%Align Technology, Inc.ALGN · $176.76-0.92%West Pharmaceutical Services, Inc.WST · $358.48-1.09%Merit Medical Systems, Inc.MMSI · $73.99-2.06%Solventum CorporationSOLV · $81.31-0.48%Lantheus Holdings, Inc.LNTH · $107.59+2.36%Boston Scientific CorporationBSX · $44.03-1.32%Medtronic plcMDT · $83.20-0.43%Becton, Dickinson and CompanyBDX · $158.17-1.10%HOYA Corporation7741.T · ¥25,215.00+0.66%EssilorLuxottica S.A.EL.PA · €166.70-1.65%